Full Press Release Details
MARINA DEL REY, Calif. , Sept. 11, 2020 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that management will be participating in two upcoming investor conferences.
Presentation details:
Event: HC Wainwright Virtual 22nd Annual Global Investment Conference Date: Tuesday, September 15, 2020 Time: 3:00-3:20pm EDT
Event: Oppenheimer Fall Healthcare Life Sciences & MedTech Summit Date: Tuesday, September 22, 2020 Time: 4:10-4:50pm EDT
About Armata Pharmaceuticals, Inc.
Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa , Staphylococcus aureus , and other pathogens. In addition, in collaboration with Merck, known as MSD outside of the United States and Canada , Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.
Media Contacts:
At Armata: Steve Martin Armata Pharmaceuticals, Inc. [email protected] 858-800-2492
Armata Investor Relations: Joyce Allaire LifeSci Advisors, LLC [email protected] 212-915-2569
SOURCE Armata Pharmaceuticals, Inc.